title: The dispositional enantioselectivity of indobufen in man.
abstract: The plasma pharmacokinetics and urinary elimination of the enantiomers of indobufen (2-[p-(1-oxo-2-isoindolinyl)-phenyl]butyric acid), a novel platelet aggregation inhibitor, have been studied in male healthy volunteers given either the racemic compound or the S-enantiomer (200 mg racemate, 100 mg S-enantiomer). Enantiospecific analysis of indobufen in plasma and urine was achieved by HPLC of its L-leucinamide diastereoisomers. After administration of the racemate, the pharmacokinetic behaviour of the R- and S-enantiomers differed, the plasma levels of the S form declining more rapidly [half-lives = 6.2 hr (S), 8.7 hr (R)]. No substantial differences were observed in terms of plasma level profile of S-indobufen when administered alone and in the racemic mixture. A statistically significant difference between the two enantiomers after administration of the racemate was found in the area under the curve (AUC), peak plasma levels (Cmax) and elimination half-life (t1/2 beta) whereas no statistically significant difference was detected in the time of peak (tmax). When the pharmacokinetic parameters Cmax, AUC, t1/2 beta and tmax of S-indobufen administered alone or as racemate were compared, there were no statistically significant differences between treatments as well as between periods and sequences. The urinary excretion of total S-indobufen (free + glucuronide) and of total R-indobufen after administration of the racemate was essentially the same. No difference was observed either in the urinary excretion of total S-indobufen after administration of the racemate or of the S-enantiomer.
authors.affiliation: Research and Development Farmitalia Carlo Erba, Erbamont Group, Milan, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Strolm Benedetti
authors.forename: E
authors.initials: E
authors.lastname: Frigerio
authors.forename: V
authors.initials: V
authors.lastname: Tamassia
authors.forename: G
authors.initials: G
authors.lastname: Noseda
authors.forename: J
authors.initials: J
authors.lastname: Caldwell
mesh_terms: D000328:Adult; D006801:Humans; D054833:Isoindoles; D010654:Phenylbutyrates / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics*; D013237:Stereoisomerism
chemical_list: D054833:Isoindoles; D010654:Phenylbutyrates; D010975:Platelet Aggregation Inhibitors; C020371:indobufen